Consider myositis if myalgia or disproportionate pain at inj site develops. May induce state of insulin resistance or hyperglycemia (observe evidence of glucose intolerance). Risk of developing diabetes in patients w/ obesity, family history of diabetes, on treatment w/ steroids or prior impaired glucose tolerance. Adjust dose of antidiabetic therapy in patients w/ pre-existing DM. Perform thyroid function test after the start of treatment & after dose adjustments. Comcomitant use of 11β-hydroxysteroid dehydrogenase type 1 & oral oestrogen. Monitor signs of malignancy relapse in patients w/ growth hormone deficiency secondary to treatment of malignant disease. Consider diagnosis of benign intracranial HTN or discontinuation if papilledema is confirmed. Monitor symptoms of intracranial HTN if growth hormone treatment is restarted for patients w/ resolved intracranial HTN. Progression of scoliosis can occur in patients who experience rapid growth. Discontinue at renal transplantation. Pregnancy & lactation. Evaluate childn who develop a limp during treatment. Ineffective for growth promotion in childn w/ closed epiphyses. Elderly >60 yr.